FDA Approves Unknown Drug — ZYDUS PHARMS
Zydus Pharmaceuticals announces approval for ANDA 218349, reflecting the company's continued strategy of leveraging generic drug pipeline expansion to diversify its market revenue …
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Zydus Pharmaceuticals announces approval for ANDA 218349, reflecting the company's continued strategy of leveraging generic drug pipeline expansion to diversify its market revenue …
Nuvalent, Inc. received FDA approval for the oral kinase inhibitor JIDEYTRO (zidesamtinib), clearing the path for its commercial launch later this year and marking a significant ex…
The FDA has granted approval to Aurobindo Pharma Limited for their generic version of adapalene and benzoyl peroxide, intensifying competition in the topical acne market. This late…
Zydus Pharmaceuticals USA Inc.’s approved ANDA for fluvoxamine maleate extended-release provides a generic alternative to the antidepressant market, effectively extending the launc…
On July 21, 2026, Novitium Pharma announced the approval of its generic drug application ANDA218495, a development likely to drive immediate revenue growth and strengthen its stand…
MSN has announced an FDA approval for the drug identified as ANDA209526, a move likely to broaden its product portfolio in the respective therapeutic segment. The approval is expec…
On July 19, 2026, financing firm Noble Gas Solutions Inc. received FDA approval for its processed substance, a regulatory milestone that is expected to bolster the company's capita…
Rising Pharmaceuticals received FDA approval for the ANDA referenced today, a generic that is not yet specified. Focus on the expected commercial impact based on the potential mark…
On July 15, 2026, Aurobindo Pharma Limited received FDA approval for its ANDA214872, marking the launch of its generic Etodolac tablets and positioning the company to capture incre…
Merck Sharp & Dohme (MSD) announced the FDA approval of LIPFENDRA (eniclitide decanoate) on July 15, 2026, a pioneering oral drug designed to delay gastric emptying to improve glyc…
On July 14, 2026, Apotex received FDA approval for ANDA 210725, positioning the company to enter the [Insert Substance] market immediately following the introduction of the referen…
Camber Pharmaceuticals, Inc. has secured FDA approval for the ANDA for afatinib dimaleate, which positions the company to enter the oral anticancer market. This approval could bols…
The FDA has granted approval to CELCUITY for its novel oral anti-cancer agent, set to launch on July 14, 2026. This strategic development positions the company to significantly dis…
Shandong announced FDA approval for its generic candidate, a milestone expected to drive revenue growth and intensify competition within the U.S. pharmaceutical market following it…
UNICHEM has received FDA approval for its Abbreviated New Drug Application No. ANDA213204 targeting the upcoming July 13, 2026 launch. This regulatory milestone positions the compa…
FDA Approves Pembrolizumab Or Pembrolizumab And Berahyaluronidase Alfa-pmph Each With Enfortumab Vedotin-ejfv For Muscle Invasive Bladder Cancer
FDA has granted approval for LAURUS's ANDA219788, slated for July 10, 2026, positioning the manufacturer to capture market share within its specific therapeutic class. Market analy…
Sagent Pharmaceuticals announced the FDA approval of Indocyanine Green (NDA 218579), expanding its portfolio of critical diagnostic products for the interstitial route. This market…
Amneal Pharmaceuticals Private Limited has secured FDA approval for its sodium bicarbonate injection, a generic version of Intravenous Sodium Bicarbonate (NDA220790), with the clea…
ADAPTIS today received FDA approval for its ANDA 217461, signaling a strategic entry into the market with implications likely driven by opportunities for generic substitution and c…